The role of simvastatin in the therapeutic approach of rheumatoid arthritis

Autoimmune Diseases

Volumn 2013, Issue , 2013, Pages

  Cojocaru, Lucia ^a   Rusali, Andrei Constantin ^a   Şuţa, Cristina ^a   Rǎdulescu, Anca Mihaela ^b   Şuţa, Maria ^a   Craiu, Elvira ^a  

^a OVIDIUS UNIVERSITY   (Romania)

^b Sf Ap Andrei County Clinical Emergency Hospital of Constanta   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; LEFLUNOMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHENIA; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DAS28; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLATULENCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PLEIOTROPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL ANALOG SCALE;

EID: 84880180990     PISSN: None     EISSN: 20900430     Source Type: Journal    
DOI: 10.1155/2013/326258     Document Type: Article

References (40)

1. McCarey D. W., Sattar N., McInnes I. B., Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? Arthritis Research and Therapy 2005 7 2 55 61 2-s2.0-15944397265 10.1186/ar1496
2. Downs J. R., Clearfield M., Weis S., Whitney E., Shapiro D. R., Beere P. A., Langendorfer A., Stein E. A., Kruyer W., Gotto A. M. Jr., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Journal of the American Medical Association 1998 279 20 1615 1622 2-s2.0-0032572086 10.1001/jama.279.20.1615
3. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., Macfarlane P. W., Mckillop J. H., Packard C. J., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The New England Journal of Medicine 1995 333 20 1301 1307 2-s2.0-0028883828 10.1056/NEJM199511163332001
4. Sever P. S., Dahlöf B., Poulter N. R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S. E., Kristinsson A., McInnes G. T., Mehlsen J., Nieminen M., O'Brien E., Östergren J., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. The Lancet 2003 361 9364 1149 1158 2-s2.0-0037420492 10.1016/S0140-6736(03)12948-0
5. Brown G., Albers J. J., Fisher L. D., Schaefer S. M., Lin J.-T., Kaplan C., Zhao X.-Q., Bisson B. D., Fitzpatrick V. F., Dodge H. T., Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England Journal of Medicine 1990 323 19 1289 1298 2-s2.0-0025183769
6. Jukema J. W., Bruschke A. V. G., van Boven A. J., Reiber J. H. C., Bal E. T., Zwinderman A. H., Jansen H., Boerma G. J. M., van Rappard F. M., Lie K. I., Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995 91 10 2528 2540 2-s2.0-0029050796
7. Herd J. A., Ballantyne C. M., Farmer J. A., Ferguson J. J. III, Jones P. H., West M. S., Gould K. L., Gotto A. M. Jr., Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS]). American Journal of Cardiology 1997 80 3 278 286 2-s2.0-0030841001 10.1016/S0002-9149(97)00346-9
8. Nissen S. E., Tuzcu E. M., Schoenhagen P., Brown B. G., Ganz P., Vogel R. A., Crowe T., Howard G., Cooper C. J., Brodie B., Grines C. L., DeMaria A. N., Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. Journal of the American Medical Association 2004 291 9 1071 1080 2-s2.0-10744225301 10.1001/jama.291.9.1071
9. Maycock C. A. A., Muhlestein J. B., Horne B. D., Carlquist J. F., Bair T. L., Pearson R. R., Li Q., Anderson J. L., Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. Journal of the American College of Cardiology 2002 40 10 1777 1785 2-s2.0-0037145887 10.1016/S0735-1097(02)02477-4
10. Vaughan C. J., Murphy M. B., Buckley B. M., Statins do more than just lower cholesterol. The Lancet 1996 348 9034 1079 1082 2-s2.0-0000306390 10.1016/S0140-6736(96)05190-2
11. Pedersen T. R., Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet 1994 344 8934 1383 1389 2-s2.0-0027987849
12. LIPID Study Group, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. The New England Journal of Medicine 1998 339 19 1349 1357
13. LaRosa J. C., Grundy S. M., Waters D. D., Shear C., Barter P., Fruchart J.-C., Gotto A. M., Greten H., Kastelein J. J. P., Shepherd J., Wenger N. K., Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England Journal of Medicine 2005 352 14 1425 1435 2-s2.0-15944410609 10.1056/NEJMoa050461
14. Pedersen T. R., Faergeman O., Kastelein J. J. P., Olsson A. G., Tikkanen M. J., Holme I., Larsen M. L., Bendiksen F. S., Lindahl C., Szarek M., Tsai J., High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Journal of the American Medical Association 2005 294 19 2437 2445 2-s2.0-27744603499 10.1001/jama.294.19.2437
15. Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M. O., Wun C.-C., Davis B. R., Braunwald E., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. The New England Journal of Medicine 1996 335 14 1001 1009 2-s2.0-0342981862 10.1056/NEJM199610033351401
16. Collins R., Armitage J., Parish S., Sleight P., Peto R., MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. The Lancet 2002 360 9326 7 22 2-s2.0-0037031061 10.1016/S0140-6736(02)09327-3
17. Schwartz G. G., Olsson A. G., Ezekowitz M. D., Ganz P., Oliver M. F., Waters D., Zeiher A., Chaitman B. R., Leslie S., Stern T., Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes the MIRACL study: a randomized controlled trial. Journal of the American Medical Association 2001 285 13 1711 1718 2-s2.0-0035804846
18. Steffens S., Mach F., Drug Insight: immunomodulatory effects of statins-potential benefits for renal patients? Nature Clinical Practice Nephrology 2006 2 7 378 387 2-s2.0-33745847843 10.1038/ncpneph0217
19. Grip O., Janciauskiene S., Lindgren S., Atorvastatin activates PPAR- γ and attenuates the inflammatory response in human monocytes. Inflammation Research 2002 51 2 58 62 2-s2.0-0036186165
20. Hilgendorff A., Muth H., Parviz B., Staubitz A., Haberbosch W., Tillmanns H., Hölschermann H., Statins differ in their ability to block NF- B activation in human blood monocytes. International Journal of Clinical Pharmacology and Therapeutics 2003 41 9 397 401 2-s2.0-0141566768
21. Leung B. P., Sattar N., Crilly A., Prach M., McCarey D. W., Payne H., Madhok R., Campbell C., Gracie J. A., Liew F. Y., McInnes I. B., A novel anti-inflammatory role for simvastatin in inflammatory arthritis. Journal of Immunology 2003 170 3 1524 1530 2-s2.0-0037309378
22. Sparrow C. P., Burton C. A., Hernandez M., Mundt S., Hassing H., Patel S., Rosa R., Hermanowski-Vosatka A., Wang P.-R., Zhang D., Peterson L., Detmers P. A., Chao Y.-S., Wright S. D., Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 1 115 121 2-s2.0-0035162266
23. Kwak B., Mulhaupt F., Myit S., Mach F., Statins as a newly recognized type of immunomodulator. Nature Medicine 2000 6 12 1399 1402 2-s2.0-0034533147 10.1038/82219
24. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., Hommel U., Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Medicine 2001 7 6 687 692 2-s2.0-0034948339 10.1038/89058
25. McInnes I. B., Leung B. P., Liew F. Y., Cell-cell interactions in synovitis. Interactions between T lymphocytes and synovial cells. Arthritis Research 2000 2 5 374 378 2-s2.0-0034469236 10.1186/ar115
26. Cobb S., Anderson F., Bayer W., Lenght of life and cause of death in rheumatoid arthritis. The New England Journal of Medicine 1953 249 14 553 556
27. Weinblatt M. E., Kuritzky L., RAPID: rheumatoid arthritis. The Journal of Family Practice 2007 56 4, supplement S1 S7 2-s2.0-34548018974
28. Solomon D. H., Karlson E. W., Rimm E. B., Cannuscio C. C., Mandl L. A., Manson J. E., Stampfer M. J., Curhan G. C., Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003 107 9 1303 1307 2-s2.0-0037432305 10.1161/01.CIR.0000054612.26458.B2
29. van Doornum S., McColl G., Wicks I. P., Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis and Rheumatism 2002 46 4 862 873 2-s2.0-0036229685 10.1002/art.10089
30. Solomon D. H., Greenberg J., Reed G., Cardiovascular risk among patients with RA in CORRONA: comparing the explanatory value of traditional cardiovascular risk factors with RA risk factors. Annals of the Rheumatic Diseases 2008 67 supplement 2, article 482
31. Kaplan M. J., Cardiovascular disease in rheumatoid arthritis. Current Opinion in Rheumatology 2006 18 3 289 297 2-s2.0-33646684974 10.1097/01.bor.0000218951.65601.bf
32. Gabriel S. E., Crowson C. S., O'Fallon W. M., Mortality in rheumatoid arthritis: have we made an impact in 4 decades? Journal of Rheumatology 1999 26 12 2529 2533 2-s2.0-0032729679
33. McInnes I. B., McCarey D. W., Sattar N., Do statins offer therapeutic potential in inflammatory arthritis? Annals of the Rheumatic Diseases 2004 63 12 1535 1537 2-s2.0-9644255832 10.1136/ard.2004.022061
34. Kanda H., Hamasaki K., Kubo K., Tateishi S., Yonezumi A., Kanda Y., Yamamoto K., Mimura T., Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. Journal of Rheumatology 2002 29 9 2024 2026 2-s2.0-0036733605
35. Abud-Mendoza C., de la Fuente H., Cuevas-Orta E., Baranda L., Cruz-Rizo J., González-Amaro R., Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003 12 8 607 611 2-s2.0-0041464676 10.1191/0961203303lu429oa
36. Tikiz C., Utuk O., Pirildar T., Bayturan O., Bayindir P., Taneli F., Tikiz H., Tuzun C., Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. Journal of Rheumatology 2005 32 11 2095 2101 2-s2.0-27744547021
37. van Doornum S., McColl G., Wicks I. P., Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2004 63 12 1571 1575 2-s2.0-9644303268 10.1136/ard.2003.018333
38. McCarey D. W., McInnes I. B., Madhok R., Hampson R., Scherbakov O., Ford I., Capell H. A., Sattar N., Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. The Lancet 2004 363 9426 2015 2021 2-s2.0-2942670131 10.1016/S0140-6736(04)16449-0
39. Charles-Schoeman C., Khanna D., Furst D. E., McMahon M., Reddy S. T., Fogelman A. M., Paulus H. E., Park G. S., Gong T., Ansell B. J., Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. Journal of Rheumatology 2007 34 7 1459 1464 2-s2.0-34447514113
40. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., Dallongeville J., de Backer G., Ebrahim S., Gjelsvik B., Herrmann-Lingen C., Hoes A., Humphries S., Knapton M., Perk J., Priori S. G., Pyorala K., Reiner Z., Ruilope L., Sans-Menendez S., Scholte Op Reimer W., Weissberg P., Wood D., Yarnell J., Zamorano J. L., European guidelines on cardiovascular disease prevention in clinical practice: executive summary. European Heart Journal 2007 28 19 2375 2414 2-s2.0-35148892823 10.1093/eurheartj/ehm316